As immunotherapies gain a stronger foothold as a treatment option for cancer, ASCO and SITC convened a panel to develop recommendations to ensure consistent and efficient clinical trial reporting in immuno-oncology.
A Delphi panel developed recommendations for integrating patients, as well as caregivers and advocate, a greater role in medical research while maintaining scientific integrity of studies.
The American Society of Clinical Oncology hosted a roundtable to develop recommendations targeted at improving patients' out-of-pocket costs for clinical trial participation.
A prospective TLN cohort study demonstrated that trial eligibility is a strong predictor of progression-free and overall survival among patients with multiple myeloma.
In this systematic review, investigators sought to determine the safety, effectiveness, and tolerability of propolis mouthwash in preventing severe oral mucositis in patients undergoing chemotherapy or radiotherapy.
What should be explained to patients regarding placebo use in controlled trials?
This fact sheet reviews cancer in adolescents and children, including possible causes, treatment, and the general outlook for childhood cancers.
A clinic staffed with clinical research nurses provided needed care for patients in clinical trials who experienced adverse effects, and also ensured consistent documentation of treatment-related AEs, according to a presentation at the 2018 ONS Annual Congress.
The importance of oncology clinical research nurses in the clinical trial process was explored in a study presented at the 2018 ONS Annual Congress.
A newly developed web site, described in a presentation at the 2018 ONS Annual Congress, aims to help nurses and patients explore clinical trial options for patients with hematologic cancers.
A randomized study evaluated the effectiveness of individual meaning-centered psychotherapy on psychological outcomes and spiritual well-being for patients with advanced cancer, compared with enhanced usual care or supportive psychotherapy.
Researchers explored the effectiveness of using a smartphone app to monitor adverse effects of patients with cancer undergoing treatment as part of a clinical trial.
Travel to appointments can be difficult for patients with cancer. In this study, researchers sought to determine the effect of travel burden on clinical trial participation by household income, race/ethnicity, and clinical trial phase.
With median age of participants in clinical trials for soft-tissue sarcoma younger than most patients who develop the disease, these researchers sought to determine the prevalence of including persons older than 65 in clinical trials and the efficacy of first-line chemotherapy for STS in older patients.
This treatment-expansion study evaluated the tolerability and safety of the PANEX (panobinostat plus bortezomib with dexamethasone) protocol in heavily treated patients with R/R multiple myeloma.
In a post-hoc analysis of the ASPIRE trial results, in which carfilzomib was discontinued due to a lack of long-term safety data, researchers present the safety and efficacy findings of KRd vs Rd for relapsed multiple myeloma at 18 months from randomization.
How is clinical trial eligibility determined?
Safety and efficacy of atezolizumab with cobimetinib for heavily pretreated metastatic CRC was demonstrated in a phase 1b study that was presented at the 2018 Gastrointestinal Cancers Symposium.
Results of the double-blind phase 3 CELESTIAL study, presented at the 2018 Gastrointestinal Cancers Symposium, demonstrated efficacy of cabozantinib in patients with HCC who were previously treated with sorafenib.
Investigators sought to determine why so few biospecimens were available for research from minority populations of women with breast cancer.
Researchers presented an update of findings in the GeparSepto trial, which seeks to determine whether improvements in pathologic complete response can be translated to a survival benefit, at SABCS 2017.
PanCan study results demonstrate the effectiveness of a novel predictive model in identifying risk of lung cancer in patients who do not meet the screening criteria of other models, including those used in the NLST.
Previous studies determined the effectiveness of 6 months of therapy with eltrombopag in patients with ITP. In this analysis, researchers extended 4 clinical trials to assess efficacy and safety of eltrombopag therapy for more than 6 months in patients with ITP.
What is a CCDR clinical trial and how does it differ from clinical trials that test new drugs?
Two phase 3 studies reveal the clinical benefit, safety profile, and overall survival of nivolumab and docetaxel for patients with squamous and nonsquamous NSCLC.
Phase 1 trials are used to determine the safety profiles of treatment regimens. In this retrospective review, investigators sought to understand the reasons participants in these studies drop out.
The first interim analysis of the ENDEAVOR trial reported superiority of carfilzomib in some outcomes; however, data on overall survival were not available. This second interim analysis reports on overall survival with carfilzomib for patients with relapsed/refractory multiple myeloma.
Insurer approval rates rose from 85 percent before Affordable Care Act to 95 percent after the health care bill was enacted.
An analysis of rates at certain milestones in clinical trials of treatments for mNSCLC suggests these rates reflect end point results for immunotherapies vs targeted and conventional therapies.
Results of a phase 2 clinical trial of savolitinib, a highly selective small molecule inhibitor of c-Met, found the agent was active and tolerable in patients with Met-driven advanced or metastatic papillary renal cell carcinoma (PRCC).
Sign Up for Free e-newsletters
- Cell Phones and Cancer Risk (Fact Sheet)
- Leukemia Risk in Children, Maternal Use of Hormonal Contraception Linked in Population Study
- ASCO, SITC Release Recommendations for Clinical Trial Reporting of Immunotherapy Adverse Events
- CheckMate 067 Gives Nivolumab Alone, With Ipilimumab the Nod in Advanced Melanoma
- New Method Estimates Risk for Breast Cancer Recurrence
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Open Hysterectomy Survival Rates Edge Minimally Invasive Procedures for Cervical Cancer
- The Efficacy and Safety of Apatinib for Refractory Malignancies: A Review and Meta-analysis
- Study Reveals Relationship of Sleep Duration, Diabetes Risk in Cancer Survivors
- Medication, Vaccination Uptake Improved by Involving Pharmacists in Elder Cancer Care
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|